Xolair 300 MG/2 ML syringe 2ML
Ended Awarded
- Contract number
- SPE2DB26FNMNK
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $22,326
Award facts
- Contract value 100% obligated
- $22,325.76 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency (DLA) awarded a delivery order valued at $22,325.76 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler headquartered in Park Ridge, Illinois, for the supply of Xolair 300 mg/2 mL syringes. The award is structured as a firm fixed-price delivery order with an ultimate completion date of November 26, 2025, and carries no set-aside designation, indicating the contractor competed in the general federal procurement marketplace. DMS Pharmaceutical Group was selected as the awardee based on its capabilities and performance under the broader Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) initiative.
This delivery order is issued under DMS Pharmaceutical Group's single-award Indefinite Delivery Contract with the DLA, designated SPE2DR, which was awarded on November 13, 2025, with a ceiling value of $499,999,999 and an ultimate completion date of December 31, 2036. The PPV-G GEN V program is a $30.3 billion acquisition strategy designed to provide Department of Defense military healthcare facilities worldwide with a comprehensive range of pharmaceutical products and medical consumables through multiple regional prime vendor contractors. DMS Pharmaceutical Group's appointment as a prime vendor positions the company as a critical supplier for DoD medical operations, with this specific delivery order for Xolair representing routine pharmaceutical supply fulfillment under that broader strategic contract vehicle.
Quick answers
Who was awarded contract SPE2DB26FNMNK?
SPE2DB26FNMNK was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on November 4, 2025.
How much is contract SPE2DB26FNMNK worth?
The government has obligated $22,326 on SPE2DB26FNMNK.
Is contract SPE2DB26FNMNK an order under another contract?
Yes. SPE2DB26FNMNK is a delivery order under SPE2DB25D9348, an indefinite delivery contract.
Was contract SPE2DB26FNMNK competed?
The extent of competition for SPE2DB26FNMNK was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award